• Vaccine Name: HIV recombinant vector vaccine MVA-gag encoding gag
• Target Pathogen: Human Immunodeficiency Virus
• Target Disease: Acquired Immunodeficiency Syndrome (AIDS)
• Vaccine Ontology ID: VO_0004347
• Type: Recombinant vector vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Macaque
• Gag from HIV 1 gene engineering:
  • Type: Recombinant vector construction
  • Description: This recombinant vector vaccine expressed gag from HIV-1 (Casimiro et al., 2003).
  • Detailed Gene Information: Click Here.
• DNA vaccine plasmid:
  • DNA vaccine plasmid name:
  • DNA vaccine plasmid VO ID: VO_0005044
• Immunization Route: Intramuscular injection (i.m.)

Monkey Response

• Vaccine Immune Response Type: VO_0000286
• Immune Response: Immunization of macaques with MVA-gag resulted in relatively weak antigen-specific T-cell responses; the levels did not exceed 150 spot-forming cells (SFC)/106 PBMCs after three doses and were significantly less than those observed in the Ad5-gag vaccinees. Only one of six MVA-gag vaccinees elicited any detectable Gag-specific antibody response (140 mMU/ml at 4 weeks post-dose 3 for monkey V215) (Casimiro et al., 2003).
• Efficacy: The study reports that SIV Gag delivered by DNA, MVA, or adenovirus type 5 vectors is able to inhibit viral replication and disease progression in rhesus macaques following challenge with the SHIV89.6P virus. However, only 50% of the animals that received MVA alone or in combination with DNA were able to effectively control viremia (Casimiro et al., 2003).